Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 1711 to 1720 of 2605 total matches.
Alefacept (Amevive) For Treatment of Psoriasis
The Medical Letter on Drugs and Therapeutics • Apr 14, 2003 (Issue 1154)
The Medical Letter
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque psoriasis.
Stalevo for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • May 10, 2004 (Issue 1182)
sleepiness (S Kaakkola, Drugs 2000; 59:1233; M Bares et al,
Fundam Clin Pharmacol 2003; 17:113; P Santens ...
Levodopa combined with carbidopa (Sinemet, and others) is the most widely used treatment for patients with Parkinson's disease, but after 2 to 5 years most patients develop troublesome complications (Treatment Guidelines from The Medical Letter 2004; 2:41). The newest treatment for Parkinson's disease patients with end-of-dose "wearing-off" is Stalevo (Novartis), a combination of the catechol-O-methyltransferase (COMT) inhibitor entacapone (Comtan) with 3 different doses of levodopa/carbidopa. The rationale for Stalevo is that it permits some patients to take only one pill rather than...
Catheter Ablation for Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jul 19, 2004 (Issue 1187)
control of atrial fibrillation with rate-slowing drugs such as digoxin or beta blockers is as effective ...
Advertisements are appearing in medical journals for continuing medical education courses on catheter ablation of atrial fibrillation. Is a cure at hand for this common disorder?
Do NSAIDs Interfere with the Cardioprotective Effects of Aspirin?
The Medical Letter on Drugs and Therapeutics • Aug 02, 2004 (Issue 1188)
used as an antiplatelet drug to reduce the risk of cardiovascular disease (Medical Letter 2000; 42:18 ...
Low-dose aspirin is widely used as an antiplatelet drug to reduce the risk of cardiovascular disease (Medical Letter 2000; 42:18). Recent reports suggest that the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen (Motrin, and others) may decrease the efficacy of aspirin for this indication. The manufacturer of Tylenol is capitalizing on these reports by advertising that aspirin-taking patients who need pain relief should use acetaminophen instead of ibuprofen.
Progesterone for Prevention of Premature Birth
The Medical Letter on Drugs and Therapeutics • May 16, 2011 (Issue 1364)
The Medical Letter®
On Drugs and Therapeutics
Volume 53 (Issue 1364)
May 16, 2011 ...
The FDA recently approved the marketing of
hydroxyprogesterone caproate injection (Makena –
Ther-Rx) for prevention of preterm birth in women
with a singleton pregnancy who have a history of singleton
spontaneous preterm birth.
Botox for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • Apr 15, 2013 (Issue 1414)
The Medical Letter®
On Drugs and Therapeutics
Volume 55 (Issue 1414)
April 15, 2013 ...
The FDA has recently approved intradetrusor injection
of onabotulinumtoxinA (Botox – Allergan) for treatment
of overactive bladder in patients who cannot tolerate or
have an inadequate response to anticholinergic therapy.
Botox is also approved by the FDA for use in
detrusor overactivity associated with a neurologic condition
such as multiple sclerosis or spinal cord injury,
and for chronic migraine, upper limb spasticity, axillary
hyperhidrosis, cervical dystonia, blepharospasm, strabismus,
and cosmetic reduction of wrinkles.
A Long-Acting Depot Formulation of Testosterone (Aveed)
The Medical Letter on Drugs and Therapeutics • Mar 31, 2014 (Issue 1439)
The Medical Letter®
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 145 ...
The FDA has approved testosterone undecanoate (Aveed –
Endo), an injectable depot formulation, for use in men
with hypogonadism who require testosterone replacement
therapy.
Reslizumab (Cinqair) for Severe Eosinophilic Asthma
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016 (Issue 1497)
The Medical Letter®
on Drugs and Therapeutics
Volume 58 (Issue 1497) June 20, 2016
Published ...
The FDA has approved reslizumab (Cinqair – Teva), a
humanized interleukin-5 (IL-5) antagonist monoclonal
antibody, for add-on maintenance treatment of severe
asthma in adults who have an eosinophilic phenotype.
It is the second IL-5 antagonist to be approved in the
US; mepolizumab (Nucala) was approved for the same
indication in 2015.
Sugammadex (Bridion) for Rapid Reversal of Neuromuscular Blockade
The Medical Letter on Drugs and Therapeutics • Aug 29, 2016 (Issue 1502)
The Medical Letter®
on Drugs and Therapeutics
Volume 58 (Issue 1502) August 29, 2016
Published ...
The FDA has approved sugammadex (Bridion – Merck),
a selective relaxant binding agent, for reversal of
rocuronium- or vecuronium-induced neuromuscular
blockade in adult surgical patients. It is the first
selective relaxant binding agent to be approved in the
US. Sugammadex has been available in the European
Union, Japan, and elsewhere for several years. Previous
FDA reviews of sugammadex did not result in approval
because of concerns about a risk of anaphylaxis and
other hypersensitivity reactions with its use.
Ciprofloxacin/Fluocinolone (Otovel) for Otitis Media with Tympanostomy Tubes
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016 (Issue 1509)
Clinical Trials
Median Time Otorrhea
Drug to Cessation Cessation Rate
Regimen of Otorrhea at Day 22 ...
The FDA has approved Otovel (Arbor), a combination
of the fluoroquinolone antibiotic ciprofloxacin 0.3% and
the corticosteroid fluocinolone acetonide 0.025%, for
otic treatment of acute otitis media with tympanostomy
tubes (AOMT) in children ≥6 months old. It is the
second fluoroquinolone/corticosteroid combination
to be approved for this indication; ciprofloxacin 0.3%/dexamethasone 0.1% (Ciprodex) has been available
for many years. In December 2015, a suspension
of ciprofloxacin 6% (Otiprio) was approved for otic
treatment of bilateral otitis media with effusion in
children...